Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Ruth Wester; Sonja Zweegman; Bronno van der Holt; Marie José Kersten; Edo Vellenga; Marinus van Marwijk-Kooy; Emelie Asselbergs; Okke de Weerdt; Monique C. Minnema; Sarah Lonergan; Antonio Palumbo; Annemiek Broijl; Pieter Sonneveld

doi:10.1097/HS9.0000000000000370

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Ruth Wester^*, Sonja Zweegman, Bronno van der Holt, Marie José Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Emelie Asselbergs, Okke de Weerdt, Monique C. Minnema, Sarah Lonergan, Antonio Palumbo, Annemiek Broijl, Pieter Sonneveld

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Original language	English
Article number	e370
Journal	HemaSphere
Volume	4
Issue number	4
DOIs	https://doi.org/10.1097/HS9.0000000000000370
Publication status	Published - Aug 2020

Bibliographical note

Access to Document

10.1097/HS9.0000000000000370Licence: CC BY-NC-ND

HemaSphere - 2020 - Wester - Carfilzomib Combined With Thalidomide and Low‐dose Dexamethasone for Remission Induction andFinal published version, 385 KBLicence: CC BY-NC-ND

Cite this

Wester, R., Zweegman, S., van der Holt, B., Kersten, M. J., Vellenga, E., van Marwijk-Kooy, M., Asselbergs, E., de Weerdt, O., Minnema, M. C., Lonergan, S., Palumbo, A., Broijl, A., & Sonneveld, P. (2020). Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. HemaSphere, 4(4), Article e370. https://doi.org/10.1097/HS9.0000000000000370

@article{abbf412959d94073bee8ffbea9e054ad,

title = "Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial",

author = "Ruth Wester and Sonja Zweegman and {van der Holt}, Bronno and Kersten, {Marie Jos{\'e}} and Edo Vellenga and {van Marwijk-Kooy}, Marinus and Emelie Asselbergs and {de Weerdt}, Okke and Minnema, {Monique C.} and Sarah Lonergan and Antonio Palumbo and Annemiek Broijl and Pieter Sonneveld",

note = "Copyright{\textcopyright}2020 the Author(s). Published by Wolters Kluwer Health, Inc. onbehalf of the European Hematology Association.",

year = "2020",

month = aug,

doi = "10.1097/HS9.0000000000000370",

language = "English",

volume = "4",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "John Wiley & Sons Inc.",

number = "4",

}

Wester, R, Zweegman, S, van der Holt, B, Kersten, MJ, Vellenga, E, van Marwijk-Kooy, M, Asselbergs, E, de Weerdt, O, Minnema, MC, Lonergan, S, Palumbo, A, Broijl, A & Sonneveld, P 2020, 'Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial', HemaSphere, vol. 4, no. 4, e370. https://doi.org/10.1097/HS9.0000000000000370

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. / Wester, Ruth; Zweegman, Sonja; van der Holt, Bronno et al.
In: HemaSphere, Vol. 4, No. 4, e370, 08.2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma

T2 - 8 vs 4 Induction Cycles; the Carthadex Trial

AU - Wester, Ruth

AU - Zweegman, Sonja

AU - van der Holt, Bronno

AU - Kersten, Marie José

AU - Vellenga, Edo

AU - van Marwijk-Kooy, Marinus

AU - Asselbergs, Emelie

AU - de Weerdt, Okke

AU - Minnema, Monique C.

AU - Lonergan, Sarah

AU - Palumbo, Antonio

AU - Broijl, Annemiek

AU - Sonneveld, Pieter

PY - 2020/8

Y1 - 2020/8

UR - http://www.scopus.com/inward/record.url?scp=85148297111&partnerID=8YFLogxK

U2 - 10.1097/HS9.0000000000000370

DO - 10.1097/HS9.0000000000000370

M3 - Article

AN - SCOPUS:85148297111

SN - 2572-9241

VL - 4

JO - HemaSphere

JF - HemaSphere

IS - 4

M1 - e370

ER -

Wester R, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, van Marwijk-Kooy M et al. Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. HemaSphere. 2020 Aug;4(4):e370. doi: 10.1097/HS9.0000000000000370

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Bibliographical note

Access to Document

Other files and links

Cite this